Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label rollover study of long-term luspatercept safety in adults with beta-thalassemia previously enrolled in luspatercept trials
MOH_2019-05-14_007137Phase 3Not yet recruiting
- Sponsor
- Celgene Corporation
- Start
- Apr 2019
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of luspatercept in beta thalassemia, sponsored by Celgene Corporation. Primary endpoint: Long-term safety of luspatercept. Planned start Apr 2019; status: not yet recruiting.
02
Drugs
luspatercept
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on MOH_2019-05-14_007137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-05-14_007137.